Navigation Links
Amarin Reports Top-Line Results of two Phase III Studies of,Miraxion in Huntington's Disease

Conference Call Begins Today at 11:00 a.m. Eastern Time

LONDON, April 24, 2007 /PRNewswire-FirstCall/ -- Amarin Corporation plc ("Amarin" or the "Company") today announces top-line results from its two Phase III clinical trials of Miraxion to treat Huntington's disease (HD). The Company conducted two Phase III double-blind, placebo-controlled studies in which HD patients were randomized to receive either placebo or 2 grams (1 gram twice daily) of Miraxion daily for six months. Study data showed no statistically significant difference in either study between Miraxion and placebo with regard to the primary and secondary endpoints.

These top-line findings are inconsistent with earlier clinical trial data that showed statistical significance in a subset of HD patients with a CAG repeat length of less than or equal to 44.

The primary endpoint of the trials was a change in the Total Motor Score 4 (TMS-4) component of the Unified Huntington's Disease Rating Scale (UHDRS). TMS-4 has been shown to be a sensitive measure of movement disorder in patients with HD. In addition, secondary endpoints included cognition and Total Functional Capacity outcomes. Miraxion was found to be safe and well-tolerated by patients.

Commenting on today's announcement, Rick Stewart, Chief Executive Officer of Amarin, said, "We are extremely surprised and disappointed by these top-line results, and we are analyzing the data in order to better understand the full and complete data set and outcomes. We are particularly disappointed that, at this time, we are not in a position to bring any positive news to those patients who are suffering from this devastating disease and to the broader HD community."

"Despite this setback with Miraxion to treat HD, we remain committed to developing Amarin's substantial central nervous system (CNS) development pipeline." commented Mr. Stewart. "We continue to evaluate the potential of
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:7/11/2014)... 2014  Veran Medical Technologies, a U.S. ... positive, cost-effective final results for the initial ... SPiNPerc endobronchial percutaneous biopsy study results support ... biopsy when a traditional bronchoscopic method is ... positive financial outcomes when more can be ...
(Date:7/10/2014)... 2014  Major advances in radiation therapy and ... highlighted in a three-day Oncology Summit taking place ... 2014.  Renowned national and international cancer experts from seven ... exchange knowledge on modern technologies making treatment for ... The Summit will address a wide ...
(Date:7/10/2014)...  Breg, Inc., a premier provider of sports ... knee brace with new innovations to help people, ... to active lifestyles.  FreeRunner,s patent-pending design acts on ... when patients need it most, and the ability ... Patellofemoral issues are the most common cause of ...
Breaking Medicine Technology:Veran Medical Publishes Lung Cancer Patient Management Study 2Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
... , , CLEVELAND, Dec. 15 At today,s ... (NYSE: LZ ), the board declared a regular quarterly ... holders of record at the close of business on February 10, ... Corporation (NYSE: LZ ) is an innovative specialty chemical ...
... , BATESVILLE, Ind., Dec. 15 Today, Hill-Rom Holdings, Inc. ... on significant strategic and financial initiatives at its Investor Conference ... Peter H. Soderberg, president and CEO of Hill-Rom, and will ... multi-year strategic initiatives Business unit, research and development and ...
Cached Medicine Technology:Lubrizol Declares Dividend 2Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 2Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 3Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 4Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 5Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 6Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 7
(Date:7/14/2014)... The Cabin Chiang Mai, Asia’s leading inpatient addiction treatment ... – a free comprehensive aftercare service for clients ... wherever they live in the world. , The Cabin ... them maintain their recovery after successfully completing primary treatment ... programme. As a chronic disease, addicts in recovery are ...
(Date:7/14/2014)... AttorneyOne.com, a recognized authority on law, update ... the FDA on Hospira Lactated Ringer’s and 5% ... 11, that one lot of Lactated Ringers and 5% ... Inc., is recalled due to mold contamination. The specific ... of fluid and electrolytes, with or without minimal carbohydrate ...
(Date:7/14/2014)... According to the Blood Pressure Solution book review recently ... a series of new information on high blood pressure ... can help readers understand more about blood pressure. The book ... methods to control hypertension naturally. , Blood ... penned by Ken Burge, a medical researcher and health consultant. ...
(Date:7/14/2014)... (PRWEB) July 14, 2014 According to the Boost ... helpful book for women who want to learn how to increase ... This book consists of 7 chapters including:, , ... Grow? , Chapter 2 – How Natural Breast Enlargement ... Your Breasts Look Bigger , Chapter 4 – The ...
(Date:7/14/2014)... "Medical devices, tests, and treatments are critical ... is a star when it comes to innovations in ... working on amazing products and ideas that are our ... to Dale Kaye CEO of the Innovation Tri-Valley ... brilliant minds and businesses that are leading society into ...
Breaking Medicine News(10 mins):Health News:The Cabin Chiang Mai Addiction Rehab Launches Industry-leading Aftercare Service 2Health News:The Cabin Chiang Mai Addiction Rehab Launches Industry-leading Aftercare Service 3Health News:Hospira Lactated Ringer’s and 5% Dextrose Injection Recalled: AttorneyOne Monitor and Keep Consumers Informed 2Health News:Hospira Lactated Ringer’s and 5% Dextrose Injection Recalled: AttorneyOne Monitor and Keep Consumers Informed 3Health News:Blood Pressure Solution Book Review Exposes Ken Burge's Hypertension Treatment Guide – Vkool.com 2Health News:Blood Pressure Solution Book Review Exposes Ken Burge's Hypertension Treatment Guide – Vkool.com 3Health News:Boost Your Bust Book Review Exposes Jenny Bolton's Breast Enhancement Guide – Vkool.com 2Health News:Boost Your Bust Book Review Exposes Jenny Bolton's Breast Enhancement Guide – Vkool.com 3Health News:Believing in the Possible – Innovation Tri-Valley’s Sixth Innovation Forum Examines the Tri-Valley’s Wealth of Innovators 2Health News:Believing in the Possible – Innovation Tri-Valley’s Sixth Innovation Forum Examines the Tri-Valley’s Wealth of Innovators 3Health News:Believing in the Possible – Innovation Tri-Valley’s Sixth Innovation Forum Examines the Tri-Valley’s Wealth of Innovators 4
... ... material testing, announced that via findings from their 3rd quarter "Packaging Quizzler" nearly half ... humidity should mimic the equivalent water content. , ... Minneapolis, MN (PRWEB) October 19, 2009 -- DDL, leader ...
... of thiopurines bears further study, researchers say , MONDAY, ... drugs to treat inflammatory bowel disease (IBD) increases the ... a new study. , IBD includes Crohn,s disease and ... immune system in order to maintain remission in IBD ...
... N.J. Oct. 19 America,s Toughest Trainer and Health ... is designed specifically for on-the-go fitness! Majesco Entertainment Company ... games for the mass market, and Interactive Game Group, ... for Nintendo DS(TM) will be available at retailers ...
... has been awarded special federal funding to support the ... Medicare Quality Improvement Organization (QIO) for the state of ... in a variety of settings. QIOs operate in all ... federal Centers for Medicare & Medicaid Services (CMS). , ...
... 19 As flu season is fast reaching its ... hold among workers, with more than 70 percent saying ... Now(SM) survey released today from ComPsych Corporation. Almost half ... and the touching of workplace surfaces in order to ...
... suggests a connection with lupus, rheumatoid arthritis , ... a link between women,s exposure to household insecticides -- ... disorders rheumatoid arthritis and lupus. , The scientist did ... and the illnesses, and it,s possible that the women ...
Cached Medicine News:Health News:DDL's 'Packaging Quizzler' Tests Medical Device Packaging Professionals' Knowledge on Appropriate Humidity Used for Accelerated Aging 2Health News:Drugs for Inflammatory Bowel Might Increase Cancer Risk 2Health News:Majesco Entertainment and Interactive Game Group Release 'Jillian Michaels Fitness Ultimatum 2010' For Nintendo DS(TM) 2Health News:Majesco Entertainment and Interactive Game Group Release 'Jillian Michaels Fitness Ultimatum 2010' For Nintendo DS(TM) 3Health News:IPRO Wins Federal Contract to Support Hospice Oversight 2Health News:New Flu Poll: Employees Avoid Each Other to Prevent Flu, Yet Almost One-Third Not Changing Behavior 2Health News:Household Insecticides May Be Linked to Autoimmune Diseases 2Health News:Household Insecticides May Be Linked to Autoimmune Diseases 3
... This microtome is the most convenient ... research and in industrial laboratories. Specimen rise ... setting from 0.5 to 12 microns in ... all MNL Freezing Stages.,Other Associated Products, ...
... The Starter Package is a ... laboratory. The package includes the Vibratome ... blocks, v-block adapter, specimen mounts w/1/2" ... for ease in all of your ...
... is a solid solution for ... package includes the Vibratome Plus, ... blocks, v-block adapter, specimen mounts ... stage assembly for ease in ...
... The Vibratome 1500 Sectioning System provides a ... animal, or plant tissues. The 1500 ... sectioning without freezing or embedding. The ... the destruction of enzyme activities, and other ...
Medicine Products: